The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca announces $50B US investment by 2030, creating thousands of jobs and building its largest drug manufacturing facility in Virginia.

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...